# Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma

> **NCT05536700** · — · UNKNOWN · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 67 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05536700
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-31
- **Primary completion:** 2022-09-17
- **Final completion:** 2022-12-31
- **Target enrollment:** 67 (ESTIMATED)
- **Last updated:** 2022-09-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05536700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05536700, "Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05536700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*